163 related articles for article (PubMed ID: 37852355)
21. KEAP1-NRF2 protein-protein interaction inhibitors: Design, pharmacological properties and therapeutic potential.
Crisman E; Duarte P; Dauden E; Cuadrado A; Rodríguez-Franco MI; López MG; León R
Med Res Rev; 2023 Jan; 43(1):237-287. PubMed ID: 36086898
[TBL] [Abstract][Full Text] [Related]
22. Discovery of Keap1-Nrf2 small-molecule inhibitors from phytochemicals based on molecular docking.
Li M; Huang W; Jie F; Wang M; Zhong Y; Chen Q; Lu B
Food Chem Toxicol; 2019 Nov; 133():110758. PubMed ID: 31412289
[TBL] [Abstract][Full Text] [Related]
23. The Keap1-Nrf2 System: A Mediator between Oxidative Stress and Aging.
Yu C; Xiao JH
Oxid Med Cell Longev; 2021; 2021():6635460. PubMed ID: 34012501
[TBL] [Abstract][Full Text] [Related]
24. Impaired antioxidant KEAP1-NRF2 system in amyotrophic lateral sclerosis: NRF2 activation as a potential therapeutic strategy.
Bono S; Feligioni M; Corbo M
Mol Neurodegener; 2021 Oct; 16(1):71. PubMed ID: 34663413
[TBL] [Abstract][Full Text] [Related]
25. Prediction of Binding Energy of Keap1 Interaction Motifs in the Nrf2 Antioxidant Pathway and Design of Potential High-Affinity Peptides.
Karttunen M; Choy WY; Cino EA
J Phys Chem B; 2018 Jun; 122(22):5851-5859. PubMed ID: 29745220
[TBL] [Abstract][Full Text] [Related]
26. Design, Synthesis, and Structure-Activity Relationships of Indoline-Based Kelch-like ECH-Associated Protein 1-Nuclear Factor (Erythroid-Derived 2)-Like 2 (Keap1-Nrf2) Protein-Protein Interaction Inhibitors.
Zhou HS; Hu LB; Zhang H; Shan WX; Wang Y; Li X; Liu T; Zhao J; You QD; Jiang ZY
J Med Chem; 2020 Oct; 63(19):11149-11168. PubMed ID: 32902980
[TBL] [Abstract][Full Text] [Related]
27. Medicinal Chemistry Insights into the Development of Small-Molecule Kelch-Like ECH-Associated Protein 1-Nuclear Factor Erythroid 2-Related Factor 2 (Keap1-Nrf2) Protein-Protein Interaction Inhibitors.
Zhao Z; Dong R; You Q; Jiang Z
J Med Chem; 2023 Jul; 66(14):9325-9344. PubMed ID: 37441735
[TBL] [Abstract][Full Text] [Related]
28. The NRF2/Keap1 pathway as a therapeutic target in inflammatory bowel disease.
Geertsema S; Bourgonje AR; Fagundes RR; Gacesa R; Weersma RK; van Goor H; Mann GE; Dijkstra G; Faber KN
Trends Mol Med; 2023 Oct; 29(10):830-842. PubMed ID: 37558549
[TBL] [Abstract][Full Text] [Related]
29. Drug-Repositioning Screening for Keap1-Nrf2 Binding Inhibitors using Fluorescence Correlation Spectroscopy.
Yoshizaki Y; Mori T; Ishigami-Yuasa M; Kikuchi E; Takahashi D; Zeniya M; Nomura N; Mori Y; Araki Y; Ando F; Mandai S; Kasagi Y; Arai Y; Sasaki E; Yoshida S; Kagechika H; Rai T; Uchida S; Sohara E
Sci Rep; 2017 Jun; 7(1):3945. PubMed ID: 28638054
[TBL] [Abstract][Full Text] [Related]
30. Pharmacological stimulation of nuclear factor (erythroid-derived 2)-like 2 translation activates antioxidant responses.
Perez-Leal O; Barrero CA; Merali S
J Biol Chem; 2017 Aug; 292(34):14108-14121. PubMed ID: 28684421
[TBL] [Abstract][Full Text] [Related]
31. Management of COVID-19-induced cytokine storm by Keap1-Nrf2 system: a review.
Singh E; Matada GSP; Abbas N; Dhiwar PS; Ghara A; Das A
Inflammopharmacology; 2021 Oct; 29(5):1347-1355. PubMed ID: 34373972
[TBL] [Abstract][Full Text] [Related]
32. Direct Keap1-kelch inhibitors as potential drug candidates for oxidative stress-orchestrated diseases: A review on In silico perspective.
Boyenle ID; Divine UC; Adeyemi R; Ayinde KS; Olaoba OT; Apu C; Du L; Lu Q; Yin X; Adelusi TI
Pharmacol Res; 2021 May; 167():105577. PubMed ID: 33774182
[TBL] [Abstract][Full Text] [Related]
33. NF-κB and Keap1 Interaction Represses Nrf2-Mediated Antioxidant Response in Rabbit Hemorrhagic Disease Virus Infection.
Hu B; Wei H; Song Y; Chen M; Fan Z; Qiu R; Zhu W; Xu W; Wang F
J Virol; 2020 May; 94(10):. PubMed ID: 32161178
[TBL] [Abstract][Full Text] [Related]
34. Phenyl Bis-Sulfonamide Keap1-Nrf2 Protein-Protein Interaction Inhibitors with an Alternative Binding Mode.
Georgakopoulos N; Talapatra S; Dikovskaya D; Dayalan Naidu S; Higgins M; Gatliff J; Ayhan A; Nikoloudaki R; Schaap M; Valko K; Javid F; Dinkova-Kostova AT; Kozielski F; Wells G
J Med Chem; 2022 May; 65(10):7380-7398. PubMed ID: 35549469
[TBL] [Abstract][Full Text] [Related]
35. Dual roles and therapeutic potential of Keap1-Nrf2 pathway in pancreatic cancer: a systematic review.
Qin JJ; Cheng XD; Zhang J; Zhang WD
Cell Commun Signal; 2019 Sep; 17(1):121. PubMed ID: 31511020
[TBL] [Abstract][Full Text] [Related]
36. KEAP1, a cysteine-based sensor and a drug target for the prevention and treatment of chronic disease.
Dayalan Naidu S; Dinkova-Kostova AT
Open Biol; 2020 Jun; 10(6):200105. PubMed ID: 32574549
[TBL] [Abstract][Full Text] [Related]
37. Targeting the KEAP1-NRF2 System to Prevent Kidney Disease Progression.
Nezu M; Suzuki N; Yamamoto M
Am J Nephrol; 2017; 45(6):473-483. PubMed ID: 28502971
[TBL] [Abstract][Full Text] [Related]
38.
Hu X; Mu L; Zhu L; Chang X; Nie L; Wang L; Li G
Mol Med Rep; 2021 Sep; 24(3):. PubMed ID: 34278476
[TBL] [Abstract][Full Text] [Related]
39. Ginsenoside CK targeting KEAP1-DGR/Kelch domain disrupts the binding between KEAP1 and NRF2-DLG motif to ameliorate oxidative stress damage.
Cheng C; Zhang J; Liu K; Xu Y; Shen F; Han Y; Hou Y; Zhang T; Bai G
Phytomedicine; 2023 Oct; 119():154992. PubMed ID: 37499433
[TBL] [Abstract][Full Text] [Related]
40. Hydrogen Sulfide Alleviates Liver Injury Through the S-Sulfhydrated-Kelch-Like ECH-Associated Protein 1/Nuclear Erythroid 2-Related Factor 2/Low-Density Lipoprotein Receptor-Related Protein 1 Pathway.
Zhao S; Song T; Gu Y; Zhang Y; Cao S; Miao Q; Zhang X; Chen H; Gao Y; Zhang L; Han Y; Wang H; Pu J; Xie L; Ji Y
Hepatology; 2021 Jan; 73(1):282-302. PubMed ID: 32219872
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
